4.8 Article

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Health Policy & Services

Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection

Dima Dandachi et al.

Summary: The study found that 61% of PWH were likely to use long-acting antiretroviral therapy, with 41% preferring pills, 40% preferring injections, and 18% preferring an implant. Most participants believed that the main benefit of long-acting therapy was eliminating the need to remember taking daily pills, but 43% expressed concerns about its effectiveness compared to pills.

AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV (2021)

Article Medicine, General & Internal

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

Chloe O. C. Orkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, General & Internal

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

Susan Swindells et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Public, Environmental & Occupational Health

A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy

Kasey R. Claborn et al.

PSYCHOLOGY HEALTH & MEDICINE (2015)